CV THERAPEUTICS, INC. as Issuer and WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION as TrusteeIndenture • August 14th, 2003 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of June 18, 2003, between CV THERAPEUTICS, INC., a corporation duly organized and existing under the laws of the State of Delaware, having its principal office at 3172 Porter Drive, Palo Alto, California 94304 (the “Issuer” or the “Company”), and WELLS FARGO BANK MINNESOTA, NATIONAL ASSOCIATION, as Trustee (the “Trustee”), having its principal corporate trust office at Sixth & Marquette, MAC N9303-120, Minneapolis, MN 55479.
PLEDGE AND ESCROW AGREEMENT by and amongPledge and Escrow Agreement • August 14th, 2003 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS PLEDGE AND ESCROW AGREEMENT (this “Agreement”), dated as of June 18, 2003, is by and among CV Therapeutics, Inc. (the “Company”), Wells Fargo Bank Minnesota, National Association, as trustee under the Indenture referred to below (the “Trustee”), and Wells Fargo Bank Minnesota, National Association, in its capacity as escrow agent (the “Escrow Agent”).
CV THERAPEUTICS, INC. $100,000,000 2.0% Senior Subordinated Convertible Debentures Due 2023 PURCHASE AGREEMENTPurchase Agreement • August 14th, 2003 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
dant or respondent, nor am I aware of any adverse judgment, decree or order currently in effect that has been issued by the FDA against the Company
REGISTRATION RIGHTS AGREEMENT amongRegistration Rights Agreement • August 14th, 2003 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Registration Rights Agreement (this “Agreement”), dated as of June 18, 2003, among CV Therapeutics, Inc., a Delaware corporation (together with any successor entity, the “Issuer”), Citigroup Global Markets Inc. (“Citigroup”), CIBC World Markets Corp., Deutsche Bank Securities Inc., First Albany Corporation, Needham & Company, Inc. and SG Cowen Securities Corporation (collectively, the “Initial Purchasers”).
